Thomas Jefferson University

EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists

Retrieved on: 
Tuesday, April 2, 2024
Patient, MIB, ARI, Therapy, AAO, Research, Surgeon, Thomas Jefferson University, German Research Foundation, Chairperson, American Diabetes Association, Macular degeneration, SAB, FACS, Food, Cornell University, Empire, University, Castle Connolly Medical, Laborie (company), Publication, Emerita, AMD, FDA, Cochrane (organisation), Moorfields Eye Hospital, American Academy, Most, Consultant, Physician, Royal college, Diabetic retinopathy, Commander, Pharmaceutical industry

WATERTOWN, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced the appointment of leading global ophthalmologists to its Scientific Advisory Board (SAB), co-chaired by Carl Regillo M.D., FACS, Chief of the Retina Service at Wills Eye Hospital and Charles Wykoff, M.D., Ph.D., Director of Research of Retina Consultants of Texas. The SAB additions include Usha Chakravarthy, M.B.B.S., Ph.D.; Allen Ho, M.D. FACS FASRS, and Frank Holz, M.D., F.E.B.O., F.A.R.V.O. These three world-renowned retinal specialists will support advancement of the Company’s global clinical strategy ahead of the anticipated initiation of its Phase 3 pivotal trials in wet age-related macular degeneration (wet AMD) in the second half of this year. Additionally, the Company announced that the U.S. Food and Drug Administration (FDA) has conditionally accepted the trade name, DURAVYUTM (vorolanib intravitreal insert) for the Company’s lead product candidate, EYP-1901.

Key Points: 
  • “The SAB’s strategic counsel, global expertise, and scientific knowledge will be incredibly valuable during this critical time in EyePoint’s growth and expansion.
  • Dr. Chakravarthy has authored or co-authored over 400 publications, and she is invited to lecture in the UK and abroad.
  • FACS FASRS is Attending Surgeon, Director of Retina Research and Co-Director of the Retina Service of Wills Eye Hospital and Professor of Ophthalmology at Thomas Jefferson University.
  • He is a Board Member of the German Ophthalmological Society, and of the Club Jules Gonin and is past president of EURETINA.

HealthTrackRx Appoints Leading Healthcare Expert Dr. Steven Goldberg as Chief Medical Officer

Retrieved on: 
Tuesday, April 9, 2024
Diagnosis, PCR, Medicine, Infection, Coventry Health Care, Thomas Jefferson University, Partnership, Georgetown University, Greater Louisville Inc., Humana, Standard of care, MD, MBA, Quality, WellCare, Express Scripts, Approximation error, Region, Kaiser Permanente, CMO, Binghamton University, Quest Diagnostics

DENTON, Texas, April 9, 2024 /PRNewswire/ -- HealthTrackRx, the nation's premier molecular diagnostic testing laboratory, today announced the appointment of Steven Goldberg, MD, MBA, as its Chief Medical Officer (CMO).

Key Points: 
  • DENTON, Texas, April 9, 2024 /PRNewswire/ -- HealthTrackRx, the nation's premier molecular diagnostic testing laboratory, today announced the appointment of Steven Goldberg, MD, MBA, as its Chief Medical Officer (CMO).
  • In the newly created role, Dr. Goldberg will lead the Company's partnership with payors, clinicians, and industry to enhance access to faster, better diagnostics.
  • A distinguished physician and respected healthcare innovator, Dr. Goldberg previously served as Chief Health Officer and Vice President of Medical Affairs at Quest Diagnostics and, preceding that, more than a decade in leading roles of several major health plans, including Chief Medical Officer at WellCare Health Plans, Senior Medical Director at Coventry Health Care, Chief of Medical Affairs at Express Scripts, Corporate Medical Director, Clinical Policy and Quality at Humana, Regional Chief Medical Officer at Excellus BCBS, Network Medical Director at Aetna Health Plans, and Medical Director at Kaiser Permanente NE.
  • "HealthTrackRx is transforming antibiotic stewardship protocols and helping payors and health plans manage spending by eliminating unnecessary tests, misdiagnosis, and ineffective antibiotic treatment.

Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients

Retrieved on: 
Monday, March 25, 2024
Diagnosis, Neurology, Sleep, Depression, Somnolence, Deficit spending, Thomas Jefferson University, Partnership, Central nervous system, NT1, Cataplexy, Patient, CNS, Sleep disorder, Cognitive deficit, Ageing, EDS, Columbia, Anxiety, Hallucination, Narcolepsy Network, Epworth Sleepiness Scale, Life, Therapy, Sleep paralysis, ESS, Medical director, Idiopathic hypersomnia, FDA, Human, Nursing

NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced topline results from the CRESCENDO (Characterizing Patient Perspectives on Unmet Needs in Narcolepsy) survey of patients with narcolepsy type 1 (NT1, i.e., narcolepsy with cataplexy) receiving treatment, demonstrating high rates of persistent symptoms and significant patient burden, despite being on current treatments. CRESCENDO was conducted in partnership with Narcolepsy Network, a national non-profit patient support organization for people with narcolepsy, idiopathic hypersomnia, and related sleep disorders.

Key Points: 
  • CRESCENDO was conducted in partnership with Narcolepsy Network, a national non-profit patient support organization for people with narcolepsy, idiopathic hypersomnia, and related sleep disorders.
  • All patients taking part in the survey were currently undergoing treatment for NT1.
  • The most common treatments were wake promoting agents (about 53% of surveyed patients), oxybates (47%), and stimulants (42%).
  • Axsome plans to present the detailed results of the CRESCENDO survey at upcoming scientific meetings.

Integrated Dermatology Appoints Nationally Renowned Healthcare Leader Tushar Ramani, M.D. as CEO

Retrieved on: 
Tuesday, March 26, 2024
General Health, Health, Practice Management, Other Health, Dermatology, Growth, Information technology, Integration, Ramani, United, Thomas Jefferson University, Physician, Management

Integrated Dermatology, the country’s largest independent dermatology provider, is pleased to announce the appointment of distinguished healthcare leader Tushar Ramani, M.D., as the company's new chief executive officer.

Key Points: 
  • Integrated Dermatology, the country’s largest independent dermatology provider, is pleased to announce the appointment of distinguished healthcare leader Tushar Ramani, M.D., as the company's new chief executive officer.
  • Ramani brings to Integrated Dermatology a unique combination of clinical expertise gained as a former anesthesiologist, along with entrepreneurial success as the founder and operator of several nationally prominent healthcare service companies.
  • In his new role, Ramani’s strategic vision will include expanding the company's dermatology partner network, implementing new technologies to enhance support services, and driving innovation while continuing to deliver high-quality dermatology care.
  • “We are thrilled to have Tushar join the Integrated team and are looking forward to working with him as he leads the Integrated Dermatology team to new heights,” Jeff Queen said.

NOWDiagnostics Welcomes Dr. Stephen S. Tang as Chairman of the Board

Retrieved on: 
Thursday, March 21, 2024
Biotechnology, General Health, Other Health, Health, Medical Supplies, College, Growth, Thomas Jefferson University, OraSure Technologies, HIV, Business, University, COVID-19, Syphilis, Research, History, Humanities, MBA, OTC, POC, Chemical engineering, Multimedia, Lehigh University, FDA, University City Science Center, Population Services International, Management

NOWDiagnostics ( NOWDx ), a developer of over-the-counter (OTC) and point-of-care (POC) diagnostics tests and first-in-class technology and platforms, today announced the appointment of Dr. Stephen S. Tang, Ph.D., MBA, as the chairman of the company’s board of directors.

Key Points: 
  • NOWDiagnostics ( NOWDx ), a developer of over-the-counter (OTC) and point-of-care (POC) diagnostics tests and first-in-class technology and platforms, today announced the appointment of Dr. Stephen S. Tang, Ph.D., MBA, as the chairman of the company’s board of directors.
  • View the full release here: https://www.businesswire.com/news/home/20240321747977/en/
    NOWDiagnostics (NOWDx) Welcomes Dr. Stephen S. Tang as Chairman of the Board (Photo: Business Wire)
    Dr. Tang is a longtime veteran of the medical diagnostic industry.
  • He led OraSure Technologies, Inc. (NASDAQ: OSUR ), a pioneer and global leader in rapid at-home tests for HIV and COVID-19, for ten years as president and CEO, chairman of the board of directors, and chairman of the compensation committee.
  • “I am delighted and enthusiastic about joining the NOWDx team as their chairman of the board,” said Dr. Tang.

ICUS Endorses Expanded Role of Sonographers in CEUS Procedures

Retrieved on: 
Thursday, March 21, 2024
Other Health, Other Science, Pharmaceutical, Other Technology, Research, Oncology, Medical Devices, Hospitals, Genetics, Stem Cells, Science, Technology, Nursing, Cardiology, General Health, Biotechnology, Health, Health Technology, Diagnosis, Radiation, Brain, Organization, Contrast-enhanced ultrasound, UEA, IPhone, Thomas Jefferson University, CEUS, Diagnostic medical sonography, SDMS, Risk, Patient, ICUS, Echocardiography, Society, GE HealthCare, CME, Scope of practice, Google Images, Agent handling, Kidney, Definity, Android, Accreditation, Medical imaging

More patients will now have access to safe and inexpensive diagnostic scans known as “contrast-enhanced ultrasound” (CEUS) as a result of the expanding role of sonographers, according to the International Contrast Ultrasound Society (ICUS).

Key Points: 
  • More patients will now have access to safe and inexpensive diagnostic scans known as “contrast-enhanced ultrasound” (CEUS) as a result of the expanding role of sonographers, according to the International Contrast Ultrasound Society (ICUS).
  • “Sonographers play a vital role in conducting CEUS examinations, and continually learning new techniques, such as CEUS, is a core component of providing innovative care and elevating our profession,” said Maria Stanczak, a member of the ICUS board of directors who played a key role in updating CEUS content in the new Scope of Practice.
  • ICUS does not charge fees for membership, CME-accredited webinars on CEUS, newsletters and other CEUS resources or programming.
  • To join ICUS, register and learn more, visit the ICUS website at www.ICUS-Society.org , or download the free ICUS app for iPhone and Android devices.

Conformal Medical's CLAAS® System Demonstrates Low Thrombogenicity Compared to Commercially Available LAAO Devices

Retrieved on: 
Wednesday, March 13, 2024
Foam, CRT, Thomas Jefferson University, DRT, Patient, Thrombosis, PET, Abstract (summary), Polytetrafluoroethylene, CLASS, JACC: Cardiovascular Interventions, Watchman, Safety, CLAAS, Medical device

NASHUA, N.H., March 13, 2024 /PRNewswire/ -- Conformal Medical, Inc. announced that the CLAAS® System was featured in a podium presentation at the Cardiovascular Research Technologies (CRT) 2024 conference. Dr. William Gray, Professor of Medicine, Thomas Jefferson University, System Chief, Cardiovascular Diseases at Main Line Health, and Co-Director Lankenau Heart Institute presented "Comparative Acute Thrombogenicity of The CLAAS Foam Implant and Watchman FLX In An In Vitro Blood Loop Model" during the conference's Best Abstracts, March 10th.

Key Points: 
  • An in vitro study compared the relative thrombogenicity of the CLAAS implant to the Watchman FLX device.
  • The CLAAS design features a foam cup with an embedded nitinol skeleton covered by a fluoropolymer (ePTFE) cover.
  • Three of each device (n=3) were inserted into an acute radiolabeled in vitro blood loop system.
  • Conformal Medical is actively enrolling patients in the CONFORM pivotal trial, evaluating the safety and efficacy of the CLAAS System compared to other commercially available LAAO devices.

Aegis Living Appoints Renowned Pulmonary and Sleep Expert Dr. Raj Dasgupta as Chief Medical Officer

Retrieved on: 
Tuesday, March 12, 2024
Internal medicine, Health, Longevity, Thomas Jefferson University, Sleep hygiene, Associate, Philosophy, Aegis, Diabetes, Television, Medicine, FACP, Research, Sleep, CNN, Columbia University, University, USC, Quality of life, Jefferson Abington Hospital, News, Michigan State University, Cognitive behavioral therapy, Mount Sinai West, FCCP, Nursing care plan, CMO, Cure, ABC News, Dementia

BELLEVUE, Wash., March 12, 2024 /PRNewswire/ -- Aegis Living, a national leader in senior assisted living and memory care, has appointed Raj "Dr. Raj" Dasgupta MD, FACP, FCCP, FAASM, as Chief Medical Officer (CMO). Dr. Raj's appointment strengthens Aegis' healthcare expertise to further integrate wellness and longevity into the care of its residents, families and team members.

Key Points: 
  • BELLEVUE, Wash., March 12, 2024 /PRNewswire/ -- Aegis Living , a national leader in senior assisted living and memory care, has appointed Raj "Dr. Raj" Dasgupta MD, FACP, FCCP, FAASM, as Chief Medical Officer (CMO).
  • While one's lifespan defines how long they will live, healthspan is the quality of life that Aegis Living aims to impact.
  • While the primary beneficiaries will be Aegis Living residents and families, Aegis also aims to support and influence team members.
  • "I am honored to join the leadership team at Aegis Living to advance the level of care and wellness not yet experienced in senior living," said Dr. Raj.

LifeStance Appoints Dr. Teresa DeLuca to Board of Directors

Retrieved on: 
Tuesday, March 12, 2024
Health, Thomas Jefferson University, Business, Patient, SVP, Research, Humana, Columbia University, MBA, DeLuca, Life, Magellan Health, Pharmacy, Drexel University, Nursing

SCOTTSDALE, Ariz., March 12, 2024 /PRNewswire/ -- LifeStance Health , one of the nation's largest providers of virtual and in-person outpatient mental healthcare, today announced that Dr. Teresa DeLuca has joined the company's board of directors.

Key Points: 
  • SCOTTSDALE, Ariz., March 12, 2024 /PRNewswire/ -- LifeStance Health , one of the nation's largest providers of virtual and in-person outpatient mental healthcare, today announced that Dr. Teresa DeLuca has joined the company's board of directors.
  • "Dr. DeLuca's background as a tenured healthcare executive and practicing psychiatrist make her a tremendous addition to our board of directors," said Ken Burdick, Chairman and CEO, LifeStance.
  • Prior to Magellan Health, Dr. DeLuca served as SVP, Health Solutions at Humana, where she oversaw sales, operations and clinical management.
  • Dr. DeLuca received an MBA from Drexel University's LeBow College of Business and her medical degree from Thomas Jefferson University.

InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, March 6, 2024
CMS, Pi, Growth, Radiology, IDE, State university system, CAD, Buffalo, PMA, MDR, TEL, Medical device regulation, Health, Stroke, CAS, TCAR, EPS, EFS, Thomas Jefferson University, European, Carotid artery stenosis, Myocardial infarction, CE marking, Vascular disease, Thrombectomy, Clinical trial, Medicaid, NPS, CEA, Good Samaritan Hospital, Stenosis, Risk, Blood vessel, Medicare, Death, Stent, Patient, Medicine, NSPR, Pharmaceutical industry

TEL AVIV, Israel and MIAMI, March 06, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the treatment of carotid artery disease (CAD) and prevention of stroke, today announced financial and operating results for the fourth quarter and full-year ended December 31, 2023.

Key Points: 
  • Fourth Quarter 2023 and Recent Developments:
    Generated record CGuard revenue in the fourth quarter 2023 of $1.76 million, a 71.6% increase over the fourth quarter of 2022.
  • Sold 3,107 CGuard EPS stent systems in the fourth quarter of 2023, as compared to 1,781 in the fourth quarter of 2022, an increase of 74.5%.
  • Financial Results for the Fourth Quarter Ended December 31, 2023
    For the fourth quarter of 2023, total revenue increased 71.6%, to $1,761,000, from $1,026,000 during the fourth quarter of 2022.
  • Total financial income for the fourth quarter of 2023 was $468,000, an increase of $349,000 or 293% compared to $119,000 for the third quarter of 2022.